RESUMO
Objective To observe the clinical effect of lansoprazole enteric -coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety .Methods Eighty patients with erosive gastritis complicated with anxiety were selected , and they were randomly divided into control group ( n =40 ) and observation group( n=40) according to the digital table .The control group was treated with lansoprazole enteric -coa-ted tablets.The observation group received lansoprazole enteric -coated tablets combined with flupentixol and melitra-cen.Hamming anxiety scale ( HAMA ) and Hamilton depression scale ( HAMD ) were used to evaluate in the two groups before and after treatment .The changes of HAMA and HAMD scores were compared between the two groups .Results Before treatment,the scores of abdominal pain ,bloating,pantothenic acid and belching had no statistically significant differences between the two groups (all P>0.05).After treatment for 4 weeks,the scores of abdominal pain,bloating, pantothenic acid and belching in the observation group were ( 0.63 ±0.12 ) points, ( 0.43 ± 0.11)points,(0.30 ±0.11)points and (0.31 ±0.14)points,respectively,which were lower than those in the control group [(1.42 ±0.18)points,(1.08 ±0.15)points,(0.79 ±0.16)points,(0.98 ±0.25)points] (t=15.396, 13.285,16.758,17.492,all P<0.05).The scores of HAMA and HAMD in the observation group were (12.15 ± 2.51)points and (14.32 ±2.51) points,respectively,which were lower than those in the control group [(19.84 ± 2.65)points,(19.84 ±3.17)points](t=20.151,21.841,all P<0.05).There was no statistically significant differ-ence in the incidence rate of adverse reactions between the two groups after treatment for 4 weeks (P >0.05) .Conclusion Lansoprazole enteric -coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety can relieve anxiety and depression ,improve clinical symptoms and treatment effect .
RESUMO
Objective To investigate the clinical curative effect of flupentixol/melitracen (deanxit) combined with mosapride citrate in the treatment of functional dyspepsia.Methods The clinical data of 240 patients with functional dyspepsia were collected,According to different treatment method,they were divided into two groups,120 patients of the control group were treated with mosapride citrate combined with omeprazole,120 patients of the observation group were treated with deanxit combined with mosapride citrate.One course of treatment was 4 weeks.After one course of treatment,the clinical curative effects and adverse reactions of the two groups were evaluated.Results After treatment,the abdominal distension,abdominal pain,early satiety,belching and other symptoms scores of the two groups were significantly lower compared with before treatment,the differences were statistically significant (all P ＜ 0.05).After treatment,the abdominal distension,abdominal pain,early satiety,belching and other symptoms scores of the observation group were significantly lower than those in the control group,the differences were statistically significant(all P ＜ 0.05).The clinical total effective rate of the observation group was 90.8％,which was significantly higher than 67.5 ％ of the control group,the difference was statistically significant (x2 =8.432,P ＜ 0.05).Before and after treatment,the liver and kidney function and blood in the urine routine examination in the two groups had no significant changes.The incidence rate of adverse reactions of the observation group was 11.67％,which of the control group was 15.83 ％,there was no statistically significant difference (x2 =0.911,P ＞ 0.05).Conclusion Deanxit combined with mosapride citrate in the treatment of functional dyspepsia is one of the important method,and its clinical effect is satisfactory,relatively safe,it is worthy of popularization and application.
RESUMO
Objective To analyse the clinical effect of Quantianma capsules combined with flupentixol and melitracen tablets on chronic migraine. Methods 130 patients with chronic migraine were treated with flupentixol and melitracen tablets, were divided into control group and observation group, 65 patients in each group. The observation group were given to Quantianma capsules. Results The effective rate of observation group with 90.77% was higher than control group with 73.85%(P<0.05). After treatment, the number of migraine attacks, duration time, VAS score, HAMA and HAMD score and mean flow velocity of cerebral artery of two groups were lower than pre-treatment and observation group were lower than that of control group(P<0.05). Adverse reactions were similar in the two groups. Conclusion Quantianma capsules can improve the efficacy of treatment of chronic migraine combined with flupentixol and melitracen tablets and improve condition with few adverse effects.
RESUMO
Objective To analyse the clinical effect of Quantianma capsules combined with flupentixol and melitracen tablets on chronic migraine. Methods 130 patients with chronic migraine were treated with flupentixol and melitracen tablets, were divided into control group and observation group, 65 patients in each group. The observation group were given to Quantianma capsules. Results The effective rate of observation group with 90.77% was higher than control group with 73.85%(P<0.05). After treatment, the number of migraine attacks, duration time, VAS score, HAMA and HAMD score and mean flow velocity of cerebral artery of two groups were lower than pre-treatment and observation group were lower than that of control group(P<0.05). Adverse reactions were similar in the two groups. Conclusion Quantianma capsules can improve the efficacy of treatment of chronic migraine combined with flupentixol and melitracen tablets and improve condition with few adverse effects.
RESUMO
Objective To study the influence analysis of patients with anxiety and depression in elderly patients with hypertension antihypertensive effect of psychological intervention combined with Flupentixol and Melitracen Tablets.Methods 60 elderly patients with hypertension accompanied by anxiety and depression in our hospital from January 2014 to December 2016 were selected as the subjects.They were randomly divided into the control group and the experimental group, with 30 patients in each group.The control group was treated with conventional antihypertensive treatment, the experimental group were given psychological intervention combined with treatment of Flupentixol and Melitracen Tablets.The clinical indexes of the experimental group and the control group were compared and analyzed.Results After the corresponding treatment, the effective rate of antihypertensive treatment in the experimental group was 28 cases, and the effective rate of depressurization was 93.3%.The effective rate of antihypertensive treatment in the control group was 21, and the effective rate of antihypertensive treatment was 70%.After treatment, the HAMD score and HAMA score of the experimental group were significantly lower than those before the treatment, and the score of the experimental group was significantly lower than that of the control group, with statistical difference(P<0.05).Conclusion The treatment of elderly hypertensive patients with anxiety and depression in patients with better antihypertensive effect of psychological intervention combined with Flupentixol and Melitracen Tablets, can improve the depression and anxiety of patients in a large extent, high safety, is further applied in clinical significance.
RESUMO
Objective To analyse clinical efficacy of Fangfengtongsheng powder combined with Flupentixol and Melitracen tablets in treatment of anorectal neurosis.Methods92 patients with anorectal neurosis from April 2014 to June 2016 were grouped two groups randomly, each with 46 cases.Two groups were treated with Flupentixol and Melitracen tablets and observation group was treated another with Fangfengtongsheng powder.Clinical efficacy of two groups were compared.Results①Total effective rate of observation group was 95.65%,higher than that of control group 78.26% (P<0.05).②After treatment,SAS and SDS score of observation group were lower than that of control group(P<0.05).③After treatment, anal bulge, anal pain, frequent defecation, anal foreign body sensation score and 8 dimensions of SF-36 scale score of observation group were better than that of control group(P<0.05).④The control group had 8.70% adverse reactions, compared with observation group 4.35%, the difference was not statistically significant.ConclusionFangfengtongsheng powder can improve the therapeutic effect of anorectal neurosis on the basis of Flupentixol and Melitracen tablets, relieve the anxiety level and improve the living standard of patients.
RESUMO
OBJECTIVE:To observe therapeutic efficacy and safety of paroxetine combined with flupentixol melitracen in the treatment of post-stroke major depressive disorder(PSMDD). METHODS:120 PSMDD patients were randomly divided into group A(40 cases),group B(40 cases)and group C(40 cases). All patients received routine stroke treatment;group A was additionally given Paroxetine hydrochloride enteric-coated sustained-release tablet 25 mg orally,once a day;group B was additionally given Flu-pentixol melitracen tablet 20 mg orally twice a day;group C was additionally given Paroxetine hydrochloride enteric-coated sus-tained-release tablet (same usage and dosage as group A)+flupentixol melitracen (same usage and dosage as group B). Three groups were treated for 28 d. Clinical efficacies of 3 groups were observed as well as NIHSS,ADL,HADM,SS-QOL score,hos-pitalization stay and the occurrence of ADR. RESULTS:Total response rate of group C was significantly higher than those of group A and B;hospitalization day was significantly less than those of group A and B,with statistical significance(P0.05). There was no statistical significance in the incidence of ADR among 3 groups (P>0.05). Before treatment,there was no statistical significance in NIHSS,ADL,HADM,SS-QOL score among 3 groups(P>0.05). After 10,28 d of treatment,NIHSS,HADM,SS-QOL score of 3 groups were significantly lower than before, above indexes were decreased gradually as time,and the group C were lower than the group A and B;ADL score of 3 groups were significantly higher than before,this index was increased gradually as time,and the group C were lower than the group A and B with statistical significance (P0.05). CONCLUSIONS:Based on routine treatment,paroxetine combined with flupentixol melitracen in the treatment of PSMDD can relieve neurologic function injury,improve depression condition and the quality of life without increasing the occurrence of ADR.
RESUMO
Objective To investigate the short and long-term effects of flupentixol-melitracen after percu-taneous coronary intervention( PCI) .Methods 86 patients with coronary heart disease who would be given PCI were randomly divided into 43 cases of the study group and 43 cases of the control group.The control group was given conventional treatment after surgery, the study group was given flupentixol -melitracen on the basis of the control group.After one course,the mental status changes and short-term effect were observed.All the patients had been follow-up for 1 year to observe the occurrence of cardiovascular events.Results After one course,the HAMA and HAMD in the study group and the control group were (7.46 ±2.53) points and (15.74 ±3.16) points,(8.03 ± 1.97)points and (16.42 ±3.67)points respectively,which in the study group were lower than the control group (t=13.413,13.208, all P <0.01 ) .The total effective rate of the study group was 97.67%, which was higher than 81.40%of the control group (χ2 =6.081,P<0.05).During follow-up,the incidence rate of adverse cardiovascular events in the study group was 6.67%,which was lower than 42.86%of the control group (χ2 =9.564,P<0.05). Conclusion The flupentixol-melitracen can effectively improve anxiety and depression, improve the recent thera-peutic effect of PCI,reduce the incidence of cardiovascular events,which worthy of promotion after PCI.
RESUMO
Objective To investigate the efficacy of flupentixol and melitracen combined with pinaverium bromide in the treatment of patients with irritable bowel syndrome. Methods A total of 64 patients with irritable bowel syndrome from October 2014 to October 2015 in department of gastroenterology of Zhuji People’s Hospital were collected and randomly divided into two groups, with 32 cases in each group.Patients in control group received with pinaverium bromide by oral, patients in combination group received flupentixol and melitracen by oral on the basis of control group.The gastrointestinal symptom rating scale (GSRS), self-rating anxiety scale (SAS), self-rating depression scale (SDS) score and clinical efficacy pre-and post-treatment were compared between two groups.Results Compared with pre-treatment, the main symptoms score in two groups decreased significantly (P<0.05); compared with control group, the main symptoms score in combination group decreased significantly(P <0.05).Compared with pre-treatment, the SAS and SDS scores decreased significantly(P <0.05); compared with control group, the SAS and SDS scores in combination group decreased significantly ( P <0.05 ) .There was no significant difference in total efficacy between control group and combination group ( 93.75%vs.81.25%, χ2 =1.237,P=0.266).There was no adverse event in two groups during treatment.Conclusion Flupentixol and melitracen combined with pinaverium bromide could significantly improve the anxiety and depression in the treatment of irritable bowel syndrome, which could promote the recovery of gastrointestinal function.
RESUMO
Objective To investigate the improvement and safety of the conventional treatment combined with Deanxit in the treatment of digestive adverse (FD) of gastrointestinal symptoms and sleep efficacy.Methods Ninety cases of patients with FD were randomly divided into the control group (pantoprazole capsule and Mosapride will + Capsule associated with sleep disorders with estazolam tablets) and observation group (pantoprazole capsule and Mosapride will + capsule with sleep disorders and estazolam tablets plus Deanxit).Both groups were treated for 4 weeks.After the course of treatment,the improvement degree and adverse reaction of digestive tract symptoms and sleep were compared between the two groups.Results After 4 weeks of treatment in the observation group with gastrointestinal symptoms were improved and the total effective rate was 86.7％,higher than that of the control group (66.7％).The difference was statistically gigmificart (P ＜ 0.05).The total effective rate of was sleep disorders improvement 83.3％,higher than that of control group (61.9％),but the difference was not statistically significant (P ＞ 0.05).Adverse reaction rates were not significantly different between the two groups.Conclusion On the basis of conventional therapy,treatment of functional dyspepsia (FD) with Deanxit can significantly alleviate gastrointestinal symptoms.Medication after 3-7 days can relieve the symptoms.After 4 weeks,the total efficiency is the highest with fewer adverse reactions.Clinical application is recommended.
RESUMO
OBJECTIVE:To observe therapeutic efficacy and safety of flupentixol and melitracen combined with pregabalin in the treatment of painful diabetic peripheral neuropathy(PDPN). METHODS:150 cases diagnosed as PDPN were selected and ran-domly divided into control group A,control group B and combination group,with 50 cases in each group. All patients received ba-sic therapy such as the control of blood glucose,blood pressure and blood lipid. Control group A was additionally given mecobala-mine 1 mg added into 0.9% Sodium chloride solution,qd,ivgtt,2 weeks later,given Mecobalamine tablet 0.5 mg,po,tid;con-trol group B was additionally given pregabalin 75 mg,po,bid;combination group was additionally given Flupentixol and melitra-cen tablet,10 mg,bid,on the basis of control group B. 3 groups were given 4 weeks treatment. After treatment,VAS score, HAMD score,and SNCV and MNVC of median nerve and peroneal nerve were compared among 3 groups. Clinical efficacy and ADR were observed. RESULTS:After treatment,VAS score and HAMD score of combination group were significantly lower than control group A and B,with statistical significance(P<0.05). SNCV and MNCV of median nerve and peroneal nerve in combina-tion group were significantly higher than in control group A and B,with statistical significance(P<0.05).The effective rate of com-bination group(90.0%)was significantly higher than that of control group A(56.0%)and B(74.0%),with statistical signifi-cance(P<0.05). No serious ADR was found in 3 groups during treatment. CONCLUSIONS:Flupentixol and melitracen combined with pregabalin have definite therapeutic efficacy in the treatment of PDPN with good safety.
RESUMO
Objective To explore the clinical effect of flupentixol and melitracen(deanxit)combined with trimebutine maleate(TMB)in the treatment of patients with functional gastrointestinal disorders(FGID).Methods 135 patients with FGID were selected,and were divided into two groups accorded to the random number method,with 68 cases in the observation group and 67 cases in the control group.The control group was treated with oryzanol and vitamin B6 ,while the observation group was treated with deanxit combine with TMB on the basis of the control group. Main symptoms of postprandial discomfort,early satiety,abdominal pain and burning sensation on the abdomen in the two groups before and after treatment were monitored,adverse reactions of two groups were recorded,and the total efficacy was evaluated after the end of treatment.Results The difference of postprandial discomfort,early satiety, abdominal pain and upper abdominal burning sensation integration between the two groups had no statistically significant before treatment(all P >0.05).After treatment,the postprandial discomfort,early satiety,the abdominal pain and epigastric burning sensation were (4.1 ±1.6)points,(3.4 ±1.1)points,(4.2 ±1.2)points and(4.4 ± 0.7)points in the observation group,which were better than (5.9 ±2.4)points,(5.3 ±1.6 )points,(6.0 ± 1.2)points and(6.1 ±0.5)points in the control group(t =3.057,4.791,5.196,9.681,all P 0.05).Conclusion Deanxit combine with TMB can significantly improve symptoms in patients with FGID,and has a significant effect,thus it is a safe and effective therapy.
RESUMO
Objective To investigate the clinical effect of flupentixol and melitracen tablets combined with macrogol 4000 powders on treatment of irritable bowel syndrome with constipation (IBS-C) in elderly patients. Methods Fifty paients aged from 65 to 95 years with IBS-C were randomly divided into 2 groups: control group (23 patients) and treatment group (27 patients). The patients in treatment group received flupentixol and melitracen tablets (1 tablets, once a day) combined with macrogol 4000 powders (1 bag/time, 2 times a day) , while the patients in control group received macrogol 4000 powders alone. The treatment period was 4 weeks. The curative effect, the scores of self-rating depression scale (SDS) and self-rating anxiety scale (SAS) and adverse reaction were compared between two groups. Results At the improvement of depressive symptoms, the effective rate in treatment group and control group was 88.9%(24/27) and 39.1%(9/23), and there was significant difference (P<0.01). At the improvement of anxiety symptoms, the effective rate in treatment group and control group was 74.1%(20/27) and 26.1%(6/23), and there was significant difference (P<0.01). The total effective rate in treatment group and control group was 88.9%(24/27) and 65.2%(15/24), and there was significant difference (P<0.05). Conclusions Flupentixol and melitracen tablets combined with macrogol 4000 powders on treatment of aged IBS-C patients have more distinguished therapeutic effect in improving constipation symptoms, stools times, anxiety and depression.
RESUMO
Objective To evaluate the clinical efficacy of flupentixol melitracen joint esomeprazole, mosapride in the treatment of refractory gastroesophageal reflux disease.Methods 80 patients with refractory gastroe-sophageal reflux disease were randomly divided into control group and observation group,40 cases in each group.Two groups of patients were given oral esomeprazole and mosapride treatment,the observation group was treated with flu-pentixol melitracen on the basis of control group.4 weeks for a course of treatment,patients were treated for 2 courses. The clinical efficacy of the two groups,the depression and anxiety RDQ score before and after treatment,the adverse reactions were recorded.Results The total effective rate of the observation group was 82.50%,which was signifi-cantly higher than 70.00% of the control group,the difference was statistically significant (χ2 =3.660,P 0.05). After treatment,the RDQ in symptom score and frequency integrator of the control group were (8.12 ±0.89)points, (7.70 ±1.00)points,compared with before treatment,the differences were significant (t =4.70,6.37,all P <0.05),and those of the observation group were (5.21 ±0.45)points,(4.71 ±0.78)points,which were significantly lower than those of the control group,the differences were statistically significant (t =1.81,1.81,all P <0.05).After treatment,the SAS score and SDS score of control group were (49.12 ±5.89)points,(50.30 ±6.00)points,com-pared with before treatment,the differences were significant (t =1.81,1.81,all P <0.05),and those of the observa-tion group were (41.21 ±5.45),(43.71 ±5.78),which were significantly lower than the control group (t =2.30, 1.91,all P <0.05).During the treatment,the adverse events in the two groups were similar,no serious adverse reac-tions were observed.Conclusion Flupentixol melitracen joint esomeprazole,mosapride in the treatment of refractory gastroesophageal reflux disease has significant clinical effect,can effectively improve the clinical symptoms of depres-sion and anxiety scores,and without significant adverse reactions,it is worthy of clinical application.
RESUMO
OBJECTIVE:To investigate the effects of hyperbaric oxygen combined with flupentixol and melitracen on depres-sion improvement,extremity motor function and ability of daily living and activity in patients with post-stroke depression (PSD). METHODS:60 PSD patients were divided into control group and observation group according to random number table,with 30 cases in each group. Both groups received routine clinical treatment,comprehensive rehabilitation therapy and psychotherapy. The control group was additionally given Flupentixol and melitracen tablets,orally,one tablet each time,in the morning;3 days later, one tablet each time,in the morning and noon,for 4 weeks. Other anti-depressive agents were not given during treatment. Observa-tion group was additionally given hyperbaric oxygen,0.12 MPa,for 90 min,qd,5 times a week,for 4 weeks,on the basis of control group. Depression degree [Hamilton depression scale (HAMD) and Self-rating depression scale(SDS)],extremity motor function [Fugl-Mayer motor function assessment (FMA)] and ability of daily living and activity [modified Barthel index (MBI)] were scored in 2 groups before and after treatment,and ADR was observed. RESULTS:After 4 weeks of treatment,HAMD and SDS of 2 groups were decreased significantly compared to before treatment,while FMA and MBI were increased significantly;the improvement of observation group was significantly better than that of control group,with statistical significance(P<0.05). No ob-vious ADR was found in 2 groups. CONCLUSIONS:Hyperbaric oxygen combined with flupentixol and melitracen can effectively improve PSD,relieve negative emotion and improve extremity motor function and ability of daily living and activity.
RESUMO
Objective To explore the clinical efficacy and safety of rabeprazole in combined with flupentixol melitracen in treatment of non -erosive gastroesophageal reflux disease with anxiety and depression.Methods 84 cases with non -erosive gastroesophageal reflux disease with anxiety and depression of outpatient and inpatient admitted from October 2012 -October 2013 and they were randomly divided into two groups according to the order,all had 42 cases.The control group was given rabeprazole treatment,observation group used flupentixol melitracen treat-ment on the basis of the control group.The clinical efficacy and the occurrence of adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 95.24%,which was significantly higher than 76.19% in the control group,the difference was significant (χ2 =11.20,P 0.05 ).Conclusion Rabe-prazole in combined with flupentixol melitracen in treatment of non -erosive gastroesophageal reflux disease with anxi-ety and depression had good effect,and the adverse reactions were mild and safe.
RESUMO
Background:Epigastric pain syndrome( EPS),a subtype of functional dyspepsia,is commonly seen in clinical practice,and severely affects patients’quality of life. Aims:To observe the therapeutic efficacy of flupentixol and melitracen combined with proton pump inhibitor on EPS and its influence on psychological status and sleep quality. Methods:A total of 118 EPS patients from Jan. 2013 to June 2014 at Huangpi District People’s Hospital were enrolled, and were randomly divided into observation group and control group. Patients in control group were given esomeprazole 20 mg/ d,while patients in observation group were given flupentixol and melitracen 10. 5 mg bid in addition to esomeprazole,the treatment course were both for 8 weeks. Psychological status,quality of sleep and clinical therapeutic efficacy were compared between the two groups. Results:Four or 8 weeks after the treatment,anxiety,depression,sleep quality and clinical symptom were significantly ameliorated than before treatment in both two groups(P < 0. 05),while anxiety,depression and clinical symptom in observation group were significantly better than those in control group(P <0. 05). Therapeutic efficacy in observation group was significantly higher than that in control group(94. 9% vs. 79. 7% , P < 0. 05). No severe adverse reactions were found in both two groups. Conclusions:Flupentixol and melitracen combined with esomeprazole can effectively ameliorate anxiety and depression,and improve the therapeutic efficacy in EPS patients.
RESUMO
Objective To investigate the therapeutic effects of Flupentixol and Melitracen with conventional medicine on functional gastrointestinal disease of officers and soldiers.Methods Eighty-two officers and soldiers with functional gastrointestinal disease which defined by the Rome Ⅲ were randomly divided into two groups.The cases in therapy group were treated with Flupentixol and Melitracen combined with conventional medicine,and the cases in control group were simply treated with conventional medicine.The scales changes of clinical eddicacy,sympotoms,depression,anxiety amd the quality of life at the beginning and 8 weeks 'treatment were recorded.Results All offers and soldiers completed the therapy,and the overall response rate was 92.68％ in the therapy group and 70.13％ in the control group(x2 =6.61,P ＜0.05).The general severity score of symptoms,the score of depression and the score of anxiety in the therapy group after treatment were significantly lower than that of before treatment (t =27.76,16.24,16.28 ; P ＜ 0.05),while there were no significant difference in the control group(P ＞ 0.05).The score of the quality of life in the therapy group (SF-36) after treatment was improved significantly than that of before treatment (P ＜ 0.05),and the difference of two group was significant (P ＞ 0.05).Conclusion The therapy scheme of Flupentixol and Melitracen with conventional medicine on offiers and soldiers with functional gastrointestinal disease can improve the total effective rate,clinical symptoms,depression,anxiety and the quality of life.
RESUMO
Objective To assess the therapeutic effects of flupentixol and melitracen tablets combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome (IBS) accompanied with anxiety and depression.Methods This multi-center,randomized,prospective study enrolled 84 patients with diarrhea-predominant IBS who were divided into combined treatment group (42 patients) and control group (42 patients).Saccharomyces boulardii was administrated in both of the groups,and flupentixol and melitracen was added in combined treatment group.The treatment course was four weeks.The gastrointestinal symptoms and mood disorders were evaluated before treatment,one week and four weeks after treatment.Adverse reactions were also observed.Chi-square test was performed for statistical analysis.Results At the end of one week after treatment,the efficacy rates of gastrointestinal symptoms improvement of combined treatment group and control group were 31.0％ (13/42) and 23.8％ (10/42),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rate of gastrointestinal symptoms improvement of combined treatment group was 92.5％ (37/40),which was higher than that of control group (73.2％,30/41),and the difference was statistically significant (x2 =5.291,P =0.037).At the end of one week after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group and control group were 31.6％ (12/38) and 12.1％ (4/33),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group was 63.9％ (23/36),which was higher than that of control group (34.4％,11/42),and the difference was statistically significant (x2 =6.433,P=0.043).At the end of one week and four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group were 35.7％ (15/42) and 80.0％ (32/40),which were higher than those of control group (15.4％,6/39 and 34.2％,13/38),and the differences were statistically significant (x2 =9.759,P=0.007; x2 =17.105,P＜0.01).One week after treatment,the adverse events rates of combined treatment group and control group were 4.8％ (2/42) and 4.8％ (2/42) ; four weeks after treatment,the adverse events rates of combined treatment group and control group were 2.5％ (1/40) and 2.4％ (1/41).There was no statistically significant difference in adverse events rates between two groups (both P＞0.05).Conclusions Flupentixol and melitracen combined with Saccharomyces boulardii treatment could not only improve the anxiety and depression symptoms of patients with diarrhea-predominant IBS,but also effectively improve gastrointestinal symptoms.The efficacy of combined treatment is better than monotherapy Saccharomyces boulardii alone treatment.
RESUMO
Background:Studies have shown that patients with peptic ulcer are susceptible to the accompanying of anxiety and depression,and affects the treatment of ulcer. Aims:To study the effect of flupentixol and melitracen combined with quadruple therapy on peptic ulcer patients with anxiety and depression. Methods:Sixty-eight peptic ulcer patients with anxiety and depression from May 2012 to May 2013 at Wuhu No. 2 People’s Hospital were enrolled,and were randomly divided into control group and observation group. Patients in control group were given quadruple therapy( rabeprazole 20 mg + amoxicillin 1. 0 g + clarithromycin 0. 5 g + colloidal bismuth subcitrate solution 10 mL,bid),while patients in observation group were given flupentixol and melitracen in addition to quadruple therapy,the treatment course were both for 2 weeks. Therapeutic efficacy of ulcer,Helicobacter pylori( Hp) eradication,therapeutic efficacy of anxiety and depression,incidence of adverse reaction and recurrence rate of ulcer within one year after treatment were compared between the two groups. Results:Compared with control group,the therapeutic efficacy of ulcer and Hp eradication in observation group were significantly increased(P < 0. 05),therapeutic efficacy of anxiety and depression was significantly increased(P < 0. 05),no significant difference in the incidence of adverse reaction was found between the two groups,and the recurrence rate of ulcer within one year was significantly decreased( P < 0. 05). Conclusions:Flupentixol and melitracen combined with quadruple therapy could significantly improve the therapeutic efficacy and effectively reduce the recurrence rate in peptic ulcer patients with anxiety and depression.